A Study to Assess the Efficacy, Safety and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Status:
Completed
Trial end date:
2020-06-08
Target enrollment:
Participant gender:
Summary
Participants with diseases characterized by chronic pruritus experiencing moderate to severe
pruritus will be enrolled in this pilot Phase 2 study.
The diseases characterized by chronic pruritus investigated in this pilot study currently
include chronic idiopathic urticaria (CIU), chronic idiopathic pruritus (CIP), lichen planus
(LP), lichen simplex chronicus (LSC) and plaque psoriasis (PPs).